Why GeneDx Holdings Stock Just Dropped 16.6%

WGS dropped 16.6% after the genetic testing company's Q3 report showed revenue in line with expectations but testing volume growth falling short, the metric investors weighted most heavily.

Revenue came in at $123.1 million, matching estimates. That print alone didn't hold the stock up. The damage came from guidance: management cut its 2026 volume growth target to at least 28%, down from the previously promised 29.2% or more.

It's the second downward revision this year. Interpretation: a repeated cut turns a single miss into a pattern, and the market is pricing the risk that volume growth keeps decelerating rather than stabilizing. The gap between the old and new targets is just 1.2 percentage points, but the direction matters more than the size, since each reduction erodes confidence in management's forecasting.

The company is still growing, and the new floor of 28% remains a sizable expansion rate. Still, the selloff shows investors are valuing WGS on volume trajectory, not on whether revenue meets consensus. In-line revenue offered no cushion once the core operating metric softened.